Prevention strategy of cardiotoxicity in cancer chemotherapy

韩尽斌; 花永强

doi:10.19401/j.cnki.1007-3639.2018.01.011

您当前的位置：

首页 >

文章列表页 >

Prevention strategy of cardiotoxicity in cancer chemotherapy

更新时间：2026-01-27

- Prevention strategy of cardiotoxicity in cancer chemotherapy
- China Oncology Vol. 28, Issue 1, Pages: 75-80(2018)
- 作者机构：
  
  1. 上海交通大学医学院附属第九人民医院中医科,上海,200033
  2. 复旦大学附属肿瘤医院中西医结合科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.01.011
  CLC： R730.53
- Published Online：07 February 2018，
  
  Published：07 February 2018
- 稿件说明：
移动端阅览
韩尽斌,吴宁,花永强,等. 肿瘤化疗药物心脏毒性的预防策略[J]. 中国癌症杂志, 2018, 28(1): 75-80.

韩尽斌, 花永强. Prevention strategy of cardiotoxicity in cancer chemotherapy[J]. China Oncology, 2018, 28(1): 75-80.
韩尽斌,吴宁,花永强,等. 肿瘤化疗药物心脏毒性的预防策略[J]. 中国癌症杂志, 2018, 28(1): 75-80. DOI： 10.19401/j.cnki.1007-3639.2018.01.011.

韩尽斌, 花永强. Prevention strategy of cardiotoxicity in cancer chemotherapy[J]. China Oncology, 2018, 28(1): 75-80. DOI： 10.19401/j.cnki.1007-3639.2018.01.011.

摘要

化疗药物的心脏毒性越来越受到关注。在临床实践中，可以通过降低药物剂量、调整给药管理和使用低毒剂型等优化化疗方案对策降低心脏毒性反应的发生率和严重程度。心脏保护剂的应用也非常重要，目前常用的药物包括右丙亚胺、心血管药物和中药制剂等，但这些药物作为心脏保护剂的应用具有局限性，且其有效性和安全性尚需要进一步验证。

Abstract

The cardiotoxicity of chemotherapeutic drugs is receiving more and more attention. The incidence and severity of cardiotoxicity can be reduced by methods such as reducing the dose of drugs

adjusting administration

and using low toxic drugs in clinical practice. Besides

appLncation of cardioprotective agents is very important and agents including cardiovascular ones

dexrazoxane as well as Chinese medicine preparations are commonly used currently. However

effects of these agents used for cardioprotection during chemotherapy are limited

and their safety needs further verification.

关键词

Keywords

references

Views

4840

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer

A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer

The progress of treatment for brain metastases of triple-negative breast cancer

Related Author

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Association Committee of Cancer Pain Fujian Anti-Cancer

Sumei FAN

Congling XIN

Laifang ZHU

Chang LIU

Rui XU

Zhengrong ZHOU

Related Institution

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰